Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined array key "thumbnail" in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 25
StackHealth / Oricell raises tens of millions to expand CAR‑T efforts

Oricell Lands $110M to Take Cell Therapy to New Territory in Cancer

Frank Vinluan / medcitynews - There are no FDA-approved therapies for GPC3, a protein highly expressed by liver cancers. Oricell Therapeutics claims its cell therapy could be best in this class, but it faces competition from companies such as AstraZeneca and Eureka Therapeutics. The p…

AI Summary: Oricell, a China‑based CAR‑T developer, secured fresh financing to accelerate its cell‑therapy programs and support plans to go public. The fundraising will bankroll clinical expansion, manufacturing scale‑up, and regulatory preparations as the company pushes toward broader development and an IPO ambition, positioning it to compete in the crowded CAR‑T market.

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #healthcarefinance #cancerresearch #researchfunding #clinicaltrials #venturecapital

In vivo CAR-T race for autoimmune grows as two RNA startups enter the clinic

6 wks / endpoints / Lei Lei Wu

On-demand GLUT3 expression augments CAR T cell metabolic fitness and antitumor efficacy in preclinical models of glioblastoma

6 wks / science / Junya Yamaguchi, Keisuke Watanabe, Akihiro Nakamura, Nina Yi-Tzu Lin, Sachi Maeda, Daisuke Sugiyama,

Allogene’s first cut of data on ‘off-the-shelf’ CAR-T shows promise

6 wks / endpoints / Lei Lei Wu

Al-Ola Abdallah: Challenges of BCMA CAR T-Cell Therapy Resistance in Multiple Myeloma

7 wks / oncodaily

Megan Melody: Long-Term Toxicities of CAR T-Cell Therapy in Focus at Mayo Clinic Meeting

7 wks / oncodaily

Jonathan Lim: HosTIL Territory – Mapping Toxicity in TIL Therapy

7 wks / oncodaily

Oricell Lands $110M to Take Cell Therapy to New Territory in Cancer

7 wks / medcitynews / Frank Vinluan

China-based CAR-T company Oricell raises $40M more as it looks to go public

7 wks / endpoints / Elizabeth Cairns

Back to Top / Saturday, April 11, 2026, 3:22 am / permalink 22053 / 8 stories in 7 wks /


Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61


Related Stories


Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Bristol Myers and Hengrui strike up to $15.2B global oncology pact / 16 days

Avalyn upsizes IPO to raise cash for lung drug trials / 29 days

Datroway secures regulatory approvals in breast cancer across US and EU / 8 days

FDA flags misleading cancer drug claims tied to biotech billionaire / 2 months

TerraPower invests $450M to build Actinium‑225 radioisotope factory / 2 months

CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 5 wks

Long‑term immunotherapy appears safe for alveolar soft part sarcoma / 5 wks

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Healthcare, Medical Devices, Biotech, Pancreatic Cancer and look for the RSS link.


↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.